Mizzou to test dog bone cancer therapy on human brain cancer
ST. LOUIS — Veterinary researchers at Mizzou have had such success with a new immunotherapy approach for bone cancer treatment in dogs, the results have now helped secure FDA approval to test the method on human brain cancer patients.
In collaboration with the biotech company ELIAS Animal Health, scientists treated 14 dogs with a personalized vaccine made from each dog’s cancer cells, according to the St. Louis Post-Dispatch. They then boosted the animal’s immune response by removing the dog’s own white blood cells, growing them in a lab, and then reinjecting them into the dog to attack the tumors. Early results suggest the treatment allows dogs to live longer than standard care.
“It’s very clear that the approach caused an immune response that extended these dogs’ lives substantially,” said principal investigator Jeffrey Bryan, a professor at the University of Missouri’s College of Veterinary Medicine.